title: Effects of acute administration of acetazolamide and frusemide on lithium clearance in humans.
abstract: To investigate the mechanism(s) of acute frusemide-induced increases in FELi, the effects of frusemide and acetazolamide, the carbonic anhydrase inhibiting agent, were evaluated in 19 healthy subjects either before or after pretreatment with acetazolamide or frusemide (11 subjects and eight subjects respectively). Acetazolamide pretreatment did not modify frusemide-induced increases in FELi (delta FLi 12.8 +/- 4.1% compared to 14.6 +/- 7.3%, P = NS); similarly, frusemide pretreatment did not modify acetazolamide-induced increases in FELi (delta FLi: 11.3 +/- 5.9% compared to 9.8 +/- 3.8%, P = NS). Acetazolamide-induced changes of FELi were correlated significantly with acetazolamide-induced increases of FEHCO3 (r = 0.61, P less than 0.05), FENa (r = 0.46, P less than 0.05) but not of FECl (r = 0.25, P = NS). On the other hand, frusemide-induced changes of FELi were correlated significantly with frusemide-induced increases of FENa (r = 0.62, P less than 0.005), FEC1 (r = 0.52, P less than 0.025) but not of FEHCO3 (r = 0.3, P = NS). Thus, frusemide effects on tubular lithium reabsorption are not related to carbonic anhydrase inhibition; furthermore, it appears that frusemide and acetazolamide affect lithium reabsorption by different and independent mechanism(s), possibly acting at different nephron site(s).
authors.affiliation: Renal Unit, Ospedale Niguarda-Ca Granda, Milan.
authors.forename: G
authors.initials: G
authors.lastname: Colussi
authors.forename: G
authors.initials: G
authors.lastname: Rombolà
authors.forename: M
authors.initials: M
authors.lastname: Surian
authors.forename: M E
authors.initials: ME
authors.lastname: De Ferrari
authors.forename: C
authors.initials: C
authors.lastname: Airaghi
authors.forename: E
authors.initials: E
authors.lastname: Benazzi
authors.forename: F
authors.initials: F
authors.lastname: Malberti
authors.forename: L
authors.initials: L
authors.lastname: Minetti
mesh_terms: D000086:Acetazolamide / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000652:urine; D000328:Adult; D001639:Bicarbonates / Q000652:urine; D004334:Drug Administration Schedule; D005260:Female; D005665:Furosemide / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000652:urine; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007684:Kidney Tubules; D007686:Kidney Tubules, Distal / Q000187:drug effects* / Q000378:metabolism; D007687:Kidney Tubules, Proximal / Q000187:drug effects* / Q000378:metabolism; D008094:Lithium / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000652:urine*; D016651:Lithium Carbonate; D008297:Male; D008875:Middle Aged; D012964:Sodium / Q000652:urine
chemical_list: D001639:Bicarbonates; D016651:Lithium Carbonate; D005665:Furosemide; D008094:Lithium; D012964:Sodium; D000086:Acetazolamide